Folate receptor targeted liposomes encapsulating anti-cancer drugs

Current Pharmaceutical Biotechnology

Volumn 16, Issue 4, 2015, Pages 333-343

  Chaudhury, Anumita ^a   Das, Surajit ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Anti cancer drugs; Drug encapsulation; Folate receptor targeting; Liposomes; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FOLATE BINDING PROTEIN; FOLATE RECEPTOR; LIPID CORE NANOCAPSULE; LIPOSOME; UNCLASSIFIED DRUG; FOLATE TRANSPORTER;

ARTICLE; CANCER THERAPY; CELL SURVIVAL; CHEMICAL INTERACTION; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; INTERNALIZATION; NANOENCAPSULATION; OVARY CANCER; PARTICLE SIZE; POLYMERIZATION; SYNTHESIS; ANIMAL; HUMAN; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FOLIC ACID TRANSPORTERS; HUMANS; LIPOSOMES;

EID: 84930985326     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201016666150118135107     Document Type: Article

References (70)

1. [1] Choi, S.W.; Mason, J.B. Folate and carcinogenesis: an integrated scheme. J. Nutr., 2000, 130, 129-132.
2. [2] Tomassetti, A.; Mangiarotti, F.; Mazzi, M.; Sforzini, S.; Miotti, S.; Galmozzi, E.; Elwood, P.C.; Canevari, S. The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human alpha-folate receptor gene in ovarian carcinoma. Cancer Res., 2003, 63, 696-704.
3. [3] Kelemen, L.E. The role of folate receptor alpha in cancer develop- ment, progression and treatment: Cause, consequence or innocent bystander? Int. J. Cancer, 2006, 119, 243-250.
4. 4[] Antony, A.C. Folate receptors. Annu. Rev. Nutr., 1996, 16, 501-521.
5. [5] Parker, N.; Turk, M.J.; Westrick, E.; Lewis, J.D.; Low, P.S.; Leamon, C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem., 2005, 338, 284-293.
6. [6] Bangham, A.D. Liposomes: the Babraham connection. Chem. Phys. Lipids, 1993, 64, 275-285.
7. [7] Bangham, A.D.; Standish, M.M.; Watkins, J.C. Diffusion of univa- lent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 1965, 13, 238-252.
8. [8] Sessa, G.; Weissmann, G. Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid. Res., 1968, 9, 310-318.
9. [9] Bangham, A.D. Membrane models with phospholipids. Prog. Bio- phys. Mol. Biol., 1968, 18, 29-95.
10. [10] Verschraegen, C.F.; Gilbert, B.E.; Loyer, E.; Huaringa, A.; Walsh, G.; Newman, R.A.; Knight, V. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res., 2004, 10, 2319-2326.
11. [11] Sadzuka, Y.; Takabe, H.; Sonobe, T. Liposomalization of SN-38 as active metabolite of CPT-11. J. Control. Rel., 2005, 108, 453-459.
12. [12] Ambegia, E.; Ansell, S.; Cullis, P.; Heyes, J.; Palmer, L.; MacLachlan, I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta, 2005, 1669, 155-163.
13. [13] Allen, T.M.; Cheng, W.W.; Hare, J.I.; Laginha, K.M. Pharmacoki-netics and pharmacodynamics of lipidic nano-particles in cancer. Anticanc. Agents Med. Chem., 2006, 6, 513-523.
14. [14] Dos Santos, N.; Waterhouse, D.; Masin, D.; Tardi, P.G.; Karlsson, G.; Edwards, K.; Bally, M.B. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J. Control. Release, 2005, 105, 89-105.
15. [15] Zhai, G.; Wu, J.; Xiang, G.; Mao, W.; Yu, B.; Li, H.; Piao, L.; Lee, L.J.; Lee, R.J. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J. Nanosci. Nanotechnol., 2009, 9, 2155-2161.
16. [16] Andresen, T.L.; Jensen, S.S.; Jorgensen, K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid Res., 2005, 44, 68-97.
17. [17] Sapra, P.; Tyagi, P.; Allen, T.M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv., 2005, 2, 369-381.
18. [18] Torchilin, V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv., 2008, 5,1003-1025.
19. [19] Low, P.S.; Antony, A.C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Deliv. Rev., 2004, 56, 1055-1058.
20. [20] Lee, R.J.; Low, P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta, 1995, 1233, 134-144.
21. [21] Gabizon, A.; Shmeeda, H.; Horowitz, A.T.; Zalipsky, S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev., 2004, 56, 1177-1192.
22. [22] Spannuth, W.A.; Sood, A.K.; Coleman, R.L. Farletuzumab in epithelial ovarian carcinoma. Expert Opin. Biol. Ther., 2010, 10, 431-437.
23. [23] Konner, J.A.; Bell-McGuinn, K.M.; Sabbatini, P.; Hensley, M.L.; Tew, W.P.; Pandit-Taskar, N.; Vander Els, N.; Phillips, M.D.; Schweizer, C.; Weil, S.C.; Larson, S.M.; Old, L.J. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: A phase I study. Clin. Cancer Res., 2010, 16, 5288-5295.
24. [24] Stephenson, S.M.; Low, P.S.; Lee, R.J. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol., 2004, 387, 33-50.
25. [25] Pan, X.Q.; Wang, H.; Lee, R.J. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res., 2003, 20, 417-422.
26. [26] Lee, R.J.; Low, P.S. Folate-targeted liposomes for drug delivery. J. Liposome Res., 1997, 7, 455-466.
27. [27] Lee, R.J.; Low, P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem., 1994, 269, 3198-3204.
28. [28] Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed., 2006, 1, 297-315.
29. [29] Dos Santos, N.; Allen, C.; Doppen, A.M.; Anantha, M.; Cox, K.A.; Gallagher, R.C.; Karlsson, G.; Edwards, K.; Kenner, G.; Samuels, L.; Webb, M.S.; Bally, M.B. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta, 2007, 1768, 1367-1377.
30. [30] Wu, J.; Liu, Q.; Lee, R.J. A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm., 2006, 316, 148-153.
31. [31] Reddy, J.A.; Abburi, C.; Hofland, H.; Howard, S.J.; Vlahov, I.; Wils, P.; Leamon, C.P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther., 2002, 9, 1542-1550.
32. [32] Leamon, C.P.; Cooper, S.R.; Hardee, G.E. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: Evaluation in vitro and in vivo. Bioconjug. Chem., 2003, 14, 738-747.
33. [33] Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6, 1949-1957.
34. [34] Chaudhury, A.; Das, S.; Bunte, R.M.; Chiu, G.N. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int. J. Nanomed., 2012, 7, 739-751.
35. [35] Chaudhury, A.; Das, S.; Lee, R.F.; Tan, K.B.; Ng, W.K.; Tan, R.B.; Chiu, G.N. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration. Int. J. Pharm., 2012, 430, 167-175.
36. [36] Chaudhury, A.; Tan, B.J.; Das, S.; Chiu, G.N. Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin. Int. J. Oncol., 2012, 40, 703-710.
37. [37] Anderson, K.E.; Eliot, L.A.; Stevenson, B.R.; Rogers, J.A. Formulation and evaluation of a folic acid receptor-targeted oral vanco-mycin liposomal dosage form. Pharm. Res., 2001, 18, 316-322.
38. [38] Gupta, Y.; Jain, A.; Jain, P.; Jain, S.K. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J. Drug Target, 2007, 15, 231-240.
39. [39] Saul, J.M.; Annapragada, A.; Natarajan, J.V.; Bellamkonda, R.V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Rel., 2003, 92, 49-67.
40. [40] Guo, W.J.; Lee, T.; Sudimack, J.; Lee, R.J. Receptor-specific delivery of liposomes via folate-PEG-Chol. J. Liposome Res., 2000, 10, 179-195.
41. [41] Shi, G.F.; Guo, W.J.; Stephenson, S.M.; Lee, R.J. Efficient intra-cellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J. Control. Rel., 2002, 80, 309-319.
42. [42] Kawano, K.; Onose, E.; Hattori, Y.; Maitani, Y. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone. Mol. Pharm., 2009, 6, 98-104.
43. [43] Gabizon, A.; Tzemach, D.; Gorin, J.; Mak, L.; Amitay, Y.; Shmeeda, H.; Zalipsky, S. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol., 2010, 66, 43-52.
44. [44] Pradhan, P.; Giri, J.; Rieken, F.; Koch, C.; Mykhaylyk, O.; Döblin-ger, M.; Banerjee, R.; Bahadur, D.; Plank, C. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J. Control. Rel., 2010, 142, 108-121.
45. [45] Bothun, G.D.; Lelis, A.; Chen, Y.; Scully, K.; Anderson, L.E.; Stoner, M.A. Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake. Nanomedicine, 2011, 7, 797-805.
46. [46] Wang, H.; Zheng, X.; Behm, F.G.; Ratnam, M. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood, 2000, 96, 3529-3536.
47. [47] Pan, X.Q.; Zheng, X.; Shi, G.F.; Wang, H.; Ratnam, M.; Lee, R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 2002, 100, 594-602.
48. [48] Lu, Y.; Wu, J.; Wu, J.; Gonit, M.; Yang, X.; Lee, A.; Xiang, G.; Li, H.; Liu, S.; Marcucci, G.; Ratnam, M.; Lee, R.J. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol. Pharm., 2007, 4, 707-712.
49. [49] Li, H.; Lu, Y.; Piao, L.; Wu, J.; Liu, S.; Marcucci, G.; Ratnam, M.; Lee, R.J. Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int. J. Pharm., 2010, 402, 57-63.
50. [50] Gabizon, A.; Horowitz, A.T.; Goren, D.; Tzemach, D.; Mandel-baum-Shavit, F.; Qazen, M.M.; Zalipsky, S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies. Bioconjug. Chem., 1999, 10, 289-298.
51. [51] Gabizon, A.; Horowitz, A.T.; Goren, D.; Tzemach, D.; Shmeeda, H.; Zalipsky, S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res., 2003, 9, 6551-6559.
52. [52] Pan, X.; Lee, R.J. Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin. Drug Deliv., 2004, 1, 7-17.
53. [53] Riviere, K.; Huang, Z.H.; Jerger, K.; Macaraeg, N.; Szoka, F.C. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration. J. Drug Target., 2011, 19, 14-24.
54. [54] Shmeeda, H.; Mak, L.; Tzemach, D.; Astrahan, P.; Tarshish, M.; Gabizon, A. Intracellular uptake and intracavitary targeting of fo-late-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther., 2006, 5, 818-824.
55. [55] Ye, P.; Zhang, W.; Yang, T.; Lu, Y.; Lu, M.; Gai, Y.; Ma, X.; Xiang, G. Folate receptor-targeted liposomes enhanced the antitu-mor potency of imatinib through the combination of active targeting and molecular targeting. Int. J. Nanomed., 2014, 9, 2167-2178.
56. [56] Zhao, X.B.; Muthusamy, N.; Byrd, J.C.; Lee, R.J. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J. Pharm. Sci., 2007, 96, 2424-2435.
57. [57] Xiang, G.; Wu, J.; Lu, Y.; Liu, Z.; Lee, R.J. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int. J. Pharm., 2008, 356, 29-36.
58. [58] Xiong, S.; Yu, B.; Wu, J.; Li, H.; Lee, R.J. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Biomed. Pharma-cother., 2011, 65, 2-8.
59. [59] Li, X.; Tian, X.; Zhang, J.; Zhao, X.; Chen, X.; Jiang, Y.; Wang, D.; Pan, W. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int. J. Nanomed., 2011, 6, 1167-1184.
60. [60] Lim, H.J.; Masin, D.; McIntosh, N.L.; Madden, T.D.; Bally, M.B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther., 2000, 292, 337-345.
61. [61] Chen, H.; Ahn, R.; Van den Bossche, J.; Thompson, D.H.; O'Hal-loran, T.V. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer Ther., 2009, 8, 1955-1963.
62. [62] Lu, Z.; Wang, J.; Wientjes, M.G.; Au, J.L.S. Intraperitoneal therapy for peritoneal cancer. Future Oncol., 2010, 6, 1625-1641.
63. [63] Pradhan, P.; Giri, J.; Rieken, F.; Koch, C.; Mykhaylyk, O.; Döblin-ger, M.; Banerjee, R.; Bahadur, D.; Plank, C. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J. Control. Rel., 2010, 142, 108-121.
64. [64] Bothun, G.D.; Lelis, A.; Chen, Y.; Scully, K.; Anderson, L.E.; Stoner, M.A. Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake. Nanomedicine, 2011, 7, 797-805.
65. [65] Yoshida, T.; Oide, N.; Sakamoto, T.; Yotsumoto, S.; Negishi, Y.; Tsuchiya, S.; Aramaki, Y. Induction of cancer cell-specific apopto-sis by folate-labeled cationic liposomes. J. Control. Rel., 2006, 111, 325-332.
66. [66] Aramaki, Y.; Takano, S.; Tsuchiya, S. Induction of apoptosis in macrophages by cationic liposomes. FEBS Lett., 1999, 460, 472-476.
67. [67] Turk, M.J.; Waters, D.J.; Low, P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett., 2004, 213, 165-172.
68. [68] Xia, W.; Hilgenbrink, A.R.; Matteson, E.L.; Lockwood, M.B.; Cheng, J.X.; Low, P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood, 2009, 113, 438-446.
69. [69] Tong, L.; Chen, W.; Wu, J.; Li, H. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells. Anticanc. Drugs, 2014, 25, 244-254.
70. [70] Li, H.; Lu, Y.; Piao, L.; Wu, J.; Liu, S.; Marcucci, G.; Ratnam, M.; Lee, R.J. Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int. J. Pharm., 2010, 402, 57-63.